November 10, 2016 08:51 AM ESTUpdated 10:01 AM

Adaptimmune surges after FDA lifts partial hold; Anthera tanks on PhIII flop; Kadmon axes staffers in restructuring

Adaptimmune stock $ADAP surged 14% after the company revealed in its Q3 update that the FDA had lifted its partial hold on its lead …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Adap­ti­m­mune surges af­ter FDA lifts par­tial hold; An­thera tanks on PhI­II flop; Kad­mon ax­es staffers in re­struc­tur­ing